At the same time, J&J delivered first-in-human results from an ongoing trial of its Omnypulse platform, featuring a large-tip catheter for focal pulsed field ablation. The Omny-IRE study included ...

Boston Scientific Corporation (NYSE: BSX) today announced positive 12-month primary endpoint results from the second phase of the ADVANTAGE AF clinical trial evaluating the use of the FARAPULSE ...

The second phase of the trial included the addition of studying the focal FARAPOINT™ Pulsed Field Ablation Catheter for cavotricuspid isthmus (CTI) ablation to treat typical atrial flutter ...

Patients who underwent radiofrequency ablation were more likely to receive cavotricuspid isthmus ablation (22.8% vs 13.7%), superior vena cava isolation (10.4% vs 4.8%), and left atrial posterior wall ...

In the U.S., the approval covers the treatment of the irregular heartbeats caused by persistent afib as well as the delivery of RF thermal ablation for cavotricuspid isthmus-dependent atrial flutter.

Medtronic announced the FDA approval of its mapping and dual-energy catheter ablation system for the treatment of persistent atrial fibrillation and radiofrequency ablation of cavotricuspid ...

GALWAY, Ireland, Oct. 24, 2024 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced United States Food and Drug Administration (FDA) approval of the ...

Results: Without nitroglycerin, cavotricuspid isthmus ablation provoked moderate-severe vasospasm in 4 of 5 (80%) patients (fractional flow reserve 0.71 ± 0.08). With repetitive nitroglycerin boluses, ...

Abstract Background —Activation mechanisms through gaps in ablation lines and resulting electrograms are poorly understood. Methods and Results —Eight patients (all men; age, 59±9 years) were studied ...